Global Healthcare Analyst

Tina Banerjee

Equity research analyst having 15+ years of experience, with an interest on fundamentally strong global healthcare companies. I have been helping investors to find future winners in healthcare space to grow their wealth by focusing on the strength and potential of the business models of the companies. My initiating coverage reports and pitch help investors to know ‘what to buy’, ‘why to buy’, and ‘when to buy’. My clients always remain on top of the sector with the help of my timely and detailed notes on earnings or any news update. I also provide broader view on the entire healthcare sector through periodic thematic reports.

Kyowa Kirin (4151 JP): 1Q26 Revenue Grow on EMEA & Out-Licensing, Guidance Partially Revised

Kyowa Kirin (4151 JP): 1H26 Revenue Grow on North America, EMEA; Guidance Reiterated

Kyowa Kirin (4151 JP): Muted 1Q25 Result; 2025 Guidance Reaffirmed; Near-Term Pain to Continue

Kyowa Kirin (4151 JP): 1H25 Stay Muted, Guidance Reaffirmed, Ziftomenib Approval Decision Awaited

Kyowa Kirin (4151 JP): Ziftomenib Approval and Commercialization A Positive, What Lies Ahead?

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/kyowa-kirin-co-ltd" target="_blank" data-smartkarma-citation="entities:18055:1" rel="noopener">Kyowa Kirin Co Ltd (4151 JP)</a> posted flat revenue in 2025. Core operating margin expands 200bps to 22.1% on lower SG&amp;A and R&amp;D expense.</li>
<li>Company announced 2026 guidance. Revenue expected to increase 4.7% to ¥520B. Higher R&amp;D is expected to drag operating profit while core profit is expected to decline 5% YoY to ¥80B.</li>
<li>New drugs Libmeldy/Lenmeldy and Phozevel are seeing strong uptake. Ziftomenib, rocatinlimab and infigratinib will drive revenue numbers in medium to long term.</li>
</ul>



Kyowa Kirin Co Ltd (4151 JP) posted flat revenue in 2025. Core operating margin expands 200bps to 22.1% on lower SG&amp;A and R&amp;D expense.
Company announced 2026 guidance. Revenue expected to increase 4.7% to ¥520B. Higher R&amp;D is expected to drag operating profit while core profit is expected to decline 5% YoY to ¥80B.
New drugs Libmeldy/Lenmeldy and Phozevel are seeing strong uptake. Ziftomenib, rocatinlimab and infigratinib will drive revenue numbers in medium to long term.


Kyowa Kirin (4151 JP): Margin Expand, Flat Revenue in 2025, Temporary Cost Burden To Be Felt in 2026